Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EBS – Emergent BioSolutions Inc.

Float Short %

19.49

Margin Of Safety %

13

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.05

EPS Last/This Y

4.79

EPS This/Next Y

-3.09

Price

9.25

Target Price

13.5

Analyst Recom

2.33

Performance Q

42

Relative Volume

0.97

Beta

1.99

Ticker: EBS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25EBS7.150.170.6316005
2025-07-28EBS6.780.180.1215925
2025-07-29EBS6.490.180.7516094
2025-07-30EBS6.070.180.5616199
2025-07-31EBS5.890.180.0316461
2025-08-01EBS5.630.180.4816650
2025-08-04EBS5.960.180.0316532
2025-08-05EBS6.090.180.0516833
2025-08-06EBS6.050.180.1017007
2025-08-07EBS8.250.180.1617218
2025-08-08EBS8.550.180.0517892
2025-08-11EBS8.180.180.2618849
2025-08-12EBS8.910.180.1118853
2025-08-13EBS8.770.180.0719455
2025-08-14EBS8.810.180.7119499
2025-08-15EBS8.860.180.0319444
2025-08-18EBS9.060.180.1716650
2025-08-19EBS9.190.180.1017010
2025-08-20EBS9.250.180.0116992
2025-08-21EBS9.310.170.0217363
2025-08-22EBS9.230.170.1017365
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25EBS7.1798.9- 0.71
2025-07-28EBS6.7698.9- 0.71
2025-07-29EBS6.5098.9- 0.71
2025-07-30EBS6.0798.9- 0.71
2025-07-31EBS5.8898.9- 0.71
2025-08-01EBS5.6378.9- 0.98
2025-08-04EBS5.9578.9- 0.98
2025-08-05EBS6.1078.9- 0.98
2025-08-06EBS6.0578.9- 0.98
2025-08-07EBS8.2478.9- 0.98
2025-08-08EBS8.5778.9- 0.98
2025-08-11EBS8.17-91.7- 0.98
2025-08-12EBS8.91-91.7- 0.98
2025-08-13EBS8.79-91.7- 0.98
2025-08-14EBS8.82-91.7- 0.98
2025-08-15EBS8.85-91.7- 1.19
2025-08-18EBS9.07-92.0- 1.19
2025-08-19EBS9.19-92.0- 1.19
2025-08-20EBS9.25-92.0- 1.19
2025-08-21EBS9.32-92.0- 1.19
2025-08-22EBS9.25-92.0- 1.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25EBS0.304.2417.44
2025-07-28EBS0.3012.2017.44
2025-07-29EBS0.3012.2017.44
2025-07-30EBS0.3012.2017.44
2025-07-31EBS0.3012.2017.44
2025-08-01EBS0.3012.2017.44
2025-08-04EBS0.3012.2617.44
2025-08-05EBS0.3012.2617.44
2025-08-06EBS0.3012.2617.44
2025-08-07EBS0.3012.2617.44
2025-08-08EBS0.3012.2617.44
2025-08-11EBS0.3112.4917.74
2025-08-12EBS0.3112.4919.49
2025-08-13EBS-0.0312.4919.49
2025-08-14EBS-0.0312.4919.49
2025-08-15EBS-0.0312.4919.49
2025-08-18EBS-0.038.6919.49
2025-08-19EBS-0.338.6919.49
2025-08-20EBS-0.348.6919.49
2025-08-21EBS-0.348.6919.49
2025-08-22EBS-0.348.6919.49
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.16

Avg. EPS Est. Current Quarter

0.11

Avg. EPS Est. Next Quarter

0.21

Insider Transactions

-0.34

Institutional Transactions

8.69

Beta

1.99

Average Sales Estimate Current Quarter

203

Average Sales Estimate Next Quarter

233

Fair Value

10.48

Quality Score

88

Growth Score

47

Sentiment Score

62

Actual DrawDown %

93

Max Drawdown 5-Year %

-98.8

Target Price

13.5

P/E

3.76

Forward P/E

9.61

PEG

P/S

0.58

P/B

0.92

P/Free Cash Flow

3.18

EPS

2.45

Average EPS Est. Cur. Y​

1.19

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.38

Relative Volume

0.97

Return on Equity vs Sector %

1.3

Return on Equity vs Industry %

18.2

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.48

EBIT Estimation

Emergent BioSolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 900
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
stock quote shares EBS – Emergent BioSolutions Inc. Stock Price stock today
news today EBS – Emergent BioSolutions Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EBS – Emergent BioSolutions Inc. yahoo finance google finance
stock history EBS – Emergent BioSolutions Inc. invest stock market
stock prices EBS premarket after hours
ticker EBS fair value insiders trading